Moreover, recent studies have shown that IL-6 inhibition with ziltivekimab in the Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition (RESCUE) has anti-inflammatory effects and decreases plasma Lp(a) dose-dependently. This evidence concerns the gene IL6 and chronic kidney disease.